Table 1.
Clinical and demographic data in the present series.
| Gender | Total | p Value | ||
|---|---|---|---|---|
| Female | Male | |||
| N | 96 | 59 | 155 | |
| Age at Amy PET | 77.9 ± 4.2 | 78.2 ± 4.4 | 78.0 ± 4.3 | 0.680 |
| Education (year) | < 0.01 | |||
| < 9 | 22 (22.9%) | 1 (1.7%) | 23 (14.8%) | |
| 9–12 | 45 (46.9%) | 26 (44.1%) | 71 (45.8%) | |
| > 12 | 29 (30.2%) | 32 (54.2%) | 61 (39.4%) | |
| MMSE at baseline | 28.5 ± 1.4 | 28.5 ± 1.6 | 28.5 ± 1.5 | 0.994 |
| APOE4 | 0.663 | |||
| Negative | 84 (87.5%) | 53 (89.8%) | 137 (88.4%) | |
| Positive | 12 (12.5%) | 6 (10.2%) | 18 (11.6%) | |
| Visual Score Amy PETa | 0.775 | |||
| Negative | 67 (69.8%) | 40 (67.8%) | 107 (69.0%) | |
| Positive | 29 (30.2%) | 19 (32.2%) | 48 (31.0%) | |
aSeventy-seven 18F-Florbetapir- (Amyvid) and seventy-eight 18F-Flutemetamol-PET (Vizamyl).